Loading...
XTSE
EDT
Market cap235mUSD
Oct 08, Last price  
1.14CAD
1D
5.56%
1Q
-15.56%
Jan 2017
314.55%
Name

Spectral Medical Inc

Chart & performance

D1W1MN
XTSE:EDT chart
P/E
—
P/S
136.98
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.32%
Rev. gr., 5y
3.05%
Revenues
2m
+6.82%
2,169,0002,993,0003,011,0003,283,0003,036,0002,430,0002,589,0002,672,0002,964,0003,089,0003,545,0003,669,0003,840,0002,868,0002,101,0001,996,0001,667,0001,598,0002,286,0002,442,000
Net income
-48m
L+209.65%
3,730,000-1,666,000-1,502,000-2,764,000-6,498,000-6,713,000-8,543,000-11,307,000-9,492,000-9,524,000-10,149,000-4,076,000-2,489,000-4,860,000-9,098,000-8,785,000-11,281,000-15,662,000-15,402,000-47,692,000
CFO
-12m
L+31.91%
-1,270,000-732,000-523,000-1,108,000-4,477,000-6,273,000-7,725,000-9,191,000-10,008,000-9,136,000-11,125,000-3,595,000-2,381,000-2,738,000-324,000-8,701,000-9,900,000-10,721,000-8,818,000-11,632,000
Dividend
Dec 19, 20110.12 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Key people

Anthony P. Bihl
Chairman of the Board · since 2013
Chris Seto
Chief Financial Officer · since 2019
Debra M. Foster
Vice President - Clinical Development · since 2011
Gualitiero Guadagni
Vice President - Sales and Marketing · since 2013
Masayuki Kaneko
Director · since 2016
William Charles Stevens
Director · since 2014
Paul M. Walker
President, Chief Executive Officer, Director
Guillermo A. Herrera
Independent Director · since 2006
URL
https://spectraldx.com/
IPO date
Jul 16, 1992
Employees
32
Domiciled in
CA
Incorporated in
CA
Headquarters & legal address
135 - 2 The West Mall
Toronto, ON M9C 1C2
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT